Benitec Biopharma (NASDAQ:BNTC – Get Free Report) and Avadel Pharmaceuticals (NASDAQ:AVDL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Earnings & Valuation
This table compares Benitec Biopharma and Avadel Pharmaceuticals”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Benitec Biopharma | $80,000.00 | 1,279.90 | -$21.75 million | ($1.91) | -5.72 |
Avadel Pharmaceuticals | $95.15 million | 13.13 | -$160.28 million | ($1.86) | -6.99 |
Benitec Biopharma has higher earnings, but lower revenue than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Profitability
This table compares Benitec Biopharma and Avadel Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Benitec Biopharma | N/A | -90.14% | -75.25% |
Avadel Pharmaceuticals | -111.64% | -122.64% | -61.29% |
Institutional & Insider Ownership
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 4.3% of Benitec Biopharma shares are held by company insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Benitec Biopharma and Avadel Pharmaceuticals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Benitec Biopharma | 0 | 0 | 5 | 1 | 3.17 |
Avadel Pharmaceuticals | 0 | 0 | 7 | 0 | 3.00 |
Benitec Biopharma currently has a consensus price target of $22.60, indicating a potential upside of 106.77%. Avadel Pharmaceuticals has a consensus price target of $24.57, indicating a potential upside of 89.01%. Given Benitec Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Avadel Pharmaceuticals.
Summary
Benitec Biopharma beats Avadel Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Benitec Biopharma
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.